Top

Published in:

Open Access 01-12-2019 | Erlotinib | Retraction Note

Retraction Note to: Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC‑1 cell apoptosis via activating the mROS‑HtrA2/Omi pathways

Authors: Jun Wan, Jie Cui, Lei Wang, Kunpeng Wu, Xiaoping Hong, Yulin Zou, Shuang Zhao, Hong Ke

Published in: Cancer Cell International | Issue 1/2019

Excerpt

The authors have retracted this article [1] because Figure 4a has been duplicated from Figure 5d in a previously published article [2]. In addition, the article contains sections that substantially overlap with the following articles (amongst others) [3‐5]. The data reported in this article are therefore unreliable. Author Hong Ke stated on behalf of all co-authors that they agree to this retraction. …

Wan J, Cui J, Wang L, et al. Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways. Cancer Cell Int. 2018;18:165. https://doi.org/10.1186/s12935-018-0665-1.CrossRefPubMedPubMedCentral

Liu J, Yan W, Zhao X, et al. Sirt3 attenuates post-infarction cardiac injury via inhibiting mitochondrial fission and normalization of AMPK–Drp1 pathways. Cell Signal. 2019;53:1. https://doi.org/10.1016/j.cellsig.2018.09.009.CrossRefPubMed

He M, Xiang Z, Xu L, et al. Lipopolysaccharide induces human olfactory ensheathing glial apoptosis by promoting mitochondrial dysfunction and activating the JNK–Bnip3–Bax pathway. Cell Stress Chaperones. 2019;24:91. https://doi.org/10.1007/s12192-018-0945-7.CrossRefPubMed

Xie Y, Lv Y, Zhang Y, et al. LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway. Biomed Pharmacother. 2019;109:679. https://doi.org/10.1016/j.biopha.2018.10.097.CrossRefPubMed

Chen Z, Wang C, Yu N, et al. INF2 regulates oxidative stress-induced apoptosis in epidermal HaCaT cells by modulating the HIF1 signaling pathway. Biomed Pharmacother. 2019;111:151. https://doi.org/10.1016/j.biopha.2018.12.046.CrossRefPubMed

Title: Retraction Note to: Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC‑1 cell apoptosis via activating the mROS‑HtrA2/Omi pathways
Authors: Jun Wan
Jie Cui
Lei Wang
Kunpeng Wu
Xiaoping Hong
Yulin Zou
Shuang Zhao
Hong Ke
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Erlotinib
Pancreatic Cancer
Pancreatic Cancer
Published in: Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-019-1019-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Extracellular and macropinocytosis internalized ATP work together to induce epithelial–mesenchymal transition and other early metastatic activities in lung cancer

Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells

The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy

Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients

Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma

Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer